News | November 21, 2023
AstraZeneca launches health-tech business ‘Evinova’
Evinova will operate as a separate health-tech business within AstraZeneca
Evinova will operate as a separate health-tech business within AstraZeneca
Decision on EU marketing authorisation expected for momelotinib by early 2024
OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program
Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
The countrywide initiative aims to spread awareness, educate the public & ensure that no one is left behind in the fight against respiratory diseases
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Collaboration enables Brenntag to serve pharma customers in EMEA with chromatography silica gels
Subscribe To Our Newsletter & Stay Updated
